Rocket Pharmaceuticals, Inc. Announces Appointment of Isabel Carmona, J.D., as Chief Human Resources Officer and Senior Vice President
September 07, 2021 at 07:00 am EDT
Share
Rocket Pharmaceuticals, Inc. announced the appointment of Isabel Carmona, J.D.,as chief human resources officer and senior vice president. Ms. Carmona brings more than 25 years of experience in human resources and organizational leadership including the last 15 years within the life sciences industry. Ms. Carmona will be responsible for all aspects of human resources, including talent acquisition, talent management and organizational development, and will serve as a key part of the leadership team. Prior to joining Rocket, Ms. Carmona was chief human resources officer of Ichnos Sciences. There, she led talent and organizational development during the spin-off, setting up and growing Ichnos Sciences as an independent oncology biotechnology company with headquarters in the U.S. and research centers around the world. Prior to that, she served in positions of increasing leadership in the global operations and human resources teams at Teva Pharmaceuticals and Shire Pharmaceuticals. Ms. Carmona has developed her career across the U.S. and Europe, where she has held leadership positions in legal, compliance, operational excellence and human resources in multiple industries including life sciences, information technology and financial services.
Rocket Pharmaceuticals, Inc. is a fully integrated, late-stage biotechnology company. The Company is advancing a sustainable pipeline of investigational genetic therapies designed to correct the root cause of complex and rare disorders. Its lentiviral (LV) vector-based gene therapies target hematologic diseases and consist of late-stage programs for Fanconi Anemia, a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer, Leukocyte Adhesion Deficiency-I (LAD-I), a severe pediatric genetic disorder that causes recurrent and life-threatening infections which are frequently fatal, and Pyruvate Kinase Deficiency (PKD), a monogenic red blood cell disorder resulting in increased red cell destruction and mild to life-threatening anemia. It also has two clinical stages and one pre-clinical stage in vivo adeno-associated virus (AAV) programs, including programs for Danon disease, Plakophilin-2 Arrhythmogenic Cardiomyopathy and BAG3 Dilated Cardiomyopathy.